114 related articles for article (PubMed ID: 25759769)
1. Imp3 expression in benign and malignant thyroid tumors and hyperplastic nodules.
Kulaçoğlu S; Erkılınç G
Balkan Med J; 2015 Jan; 32(1):30-7. PubMed ID: 25759769
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors.
Slosar M; Vohra P; Prasad M; Fischer A; Quinlan R; Khan A
Endocr Pathol; 2009; 20(3):149-57. PubMed ID: 19449140
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of IMP3 expression in thyroid neoplasms: a quantitative RT-PCR study.
Jin L; Seys AR; Zhang S; Erickson-Johnson MR; Roth CW; Evers BR; Oliveira AM; Lloyd RV
Diagn Mol Pathol; 2010 Jun; 19(2):63-9. PubMed ID: 20502182
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
Abd-El Raouf SM; Ibrahim TR
Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil gelatinase-associated lipocalin (NGAL) immunohistochemical expression in follicular cell-derived thyroid tumors: a novel diagnostic tool?
Barresi V; Leni A; Tuccari G; Barresi G
Histol Histopathol; 2012 Mar; 27(3):329-36. PubMed ID: 22237710
[TBL] [Abstract][Full Text] [Related]
6. CD56 expression in benign and malignant thyroid lesions.
Muthusamy S; Azhar Sha S; Abdullah Suhaimi SN; Kassim N; Mahasin M; Mohd Saleh MF; Md Isa N
Malays J Pathol; 2018 Aug; 40(2):111-119. PubMed ID: 30173227
[TBL] [Abstract][Full Text] [Related]
7. The diagnostic utility of combination of HMGA2 and IMP3 qRT-PCR testing in thyroid neoplasms.
Jin L; Lloyd RV; Henry MR; Erickson LA; Sebo TJ; Rumilla KM; Zhang J
Appl Immunohistochem Mol Morphol; 2015 Jan; 23(1):36-43. PubMed ID: 25356939
[TBL] [Abstract][Full Text] [Related]
8. Retinoblastoma expression in thyroid neoplasms.
Anwar F; Emond MJ; Schmidt RA; Hwang HC; Bronner MP
Mod Pathol; 2000 May; 13(5):562-9. PubMed ID: 10824929
[TBL] [Abstract][Full Text] [Related]
9. IMP3 expression in serous tumors of the ovary.
Chisté M; Alexis J; Recine M
Appl Immunohistochem Mol Morphol; 2014 Oct; 22(9):658-62. PubMed ID: 25279713
[TBL] [Abstract][Full Text] [Related]
10. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma.
Chiappetta G; Tallini G; De Biasio MC; Manfioletti G; Martinez-Tello FJ; Pentimalli F; de Nigris F; Mastro A; Botti G; Fedele M; Berger N; Santoro M; Giancotti V; Fusco A
Cancer Res; 1998 Sep; 58(18):4193-8. PubMed ID: 9751634
[TBL] [Abstract][Full Text] [Related]
11. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.
Mataraci EA; Ozgüven BY; Kabukçuoglu F
Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608
[TBL] [Abstract][Full Text] [Related]
12. [Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses].
Teng XD; Wang LJ; Yao HT; Li J; Ding W; Yan LP
Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):212-6. PubMed ID: 15256110
[TBL] [Abstract][Full Text] [Related]
13. A six-gene model for differentiating benign from malignant thyroid tumors on the basis of gene expression.
Rosen J; He M; Umbricht C; Alexander HR; Dackiw AP; Zeiger MA; Libutti SK
Surgery; 2005 Dec; 138(6):1050-6; discussion 1056-7. PubMed ID: 16360390
[TBL] [Abstract][Full Text] [Related]
14. Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors.
Li L; Xu H; Spaulding BO; Cheng L; Simon R; Yao JL; di Sant'Agnese PA; Bourne PA; Huang J
Hum Pathol; 2008 Aug; 39(8):1205-11. PubMed ID: 18547613
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms.
Kebebew E; Peng M; Reiff E; Duh QY; Clark OH; McMillan A
Surgery; 2005 Dec; 138(6):1102-9; discussion 1109-10. PubMed ID: 16360397
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of S100C in thyroid lesions.
Torres-Cabala C; Panizo-Santos A; Krutzsch HC; Barazi H; Namba M; Sakaguchi M; Roberts DD; Merino MJ
Int J Surg Pathol; 2004 Apr; 12(2):107-15. PubMed ID: 15173915
[TBL] [Abstract][Full Text] [Related]
17. Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules.
Finley DJ; Arora N; Zhu B; Gallagher L; Fahey TJ
J Clin Endocrinol Metab; 2004 Jul; 89(7):3214-23. PubMed ID: 15240595
[TBL] [Abstract][Full Text] [Related]
18. Utility of contrast-enhanced ultrasound for evaluation of thyroid nodules.
Zhang B; Jiang YX; Liu JB; Yang M; Dai Q; Zhu QL; Gao P
Thyroid; 2010 Jan; 20(1):51-7. PubMed ID: 20067379
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules.
Park YJ; Kwak SH; Kim DC; Kim H; Choe G; Park DJ; Jang HC; Park SH; Cho BY; Park SY
J Korean Med Sci; 2007 Aug; 22(4):621-8. PubMed ID: 17728499
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of IMP3 and p53 in inflammatory lesions and neoplastic lesions of the gastric mucosa.
Strehl JD; Hoegel J; Hornicek I; Hartmann A; Riener MO
Int J Clin Exp Pathol; 2014; 7(5):2091-101. PubMed ID: 24966917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
